In order to test the efficacy of fenclofenac in patients with rheumatoid arthritis, a two-part trial was planned; firstly to compare fenclofenac with an identical placebo, and secondly to compare it with an established propionic acid derivative (naproxen).
Patients and Methods
Patients attending the rheumatology out-patient clinic were invited to take part in the trial. All were suffering from 'definite' or 'classical' rheumatoid arthritis, according to the criteria of the American Rheumatism Association (Ropes et al. 1958) . All had active disease with a less than optimal response to their current therapy. Pregnant women, patients with chronic gastrointestinal symptoms, or with hepatic or renal dysfunction, were excluded, as were those receiving gold therapy, corticosteroids, antimalarials, D-penicillamine, or cytotoxic drugs either currently or within the previous three months. All patients gave fully informed consent.
Paracetamol, up to 4 g daily, was allowed as a supplementary analgesic; all other anti-rheumatic drugs were stopped for the duration of the trial. No patient took part in both trials.
Trial Design
Both trials were randomized, double-blind, crossover studies with fourteen days on each preparation following a three-day run-in period, during which the patient took only paracetamol for symptomatic relief. Trial 1: Fenclofenac 900 mg daily (300 mg at 8 a.m., and 600 mg at 8 p.m.) v. identical placebo tablets.
Trial 2: Fenclofenac 1200 mg daily (600 mg twice daily) v. naproxen 500 mg daily (250 mg twice daily).
The tablets were concealed in rice-paper cachets. Two cachets were taken morning and evening, containing either two 300 mg fenclofenac tablets or one 250 mg naproxen tablet and one dummy.
In order to minimize the practical and ethical problems of treating patients with rheumatoid arthritis with less effective drugs or placebos, each trial was analysed sequentially by plotting each patient's overall preference for one treatment period or the other on an Armitage restricted plan (Armitage 1975 ): 2a = 0.05, 1-,B = 0.95, O = 0.80. The trial was stopped as soon as a significant result in favour of one drug or the other was reached.
Patients were assessed at the beginning of the trial, at the end of the first fortnight, and at the end of the trial. The parameters recorded at each visit are shown in Table 1 . In addition to these parameters, liver function tests, plasma urea and electrolytes and rheumatoid factor were recorded at the initial visit, and the patient's overall preference noted at the final visit.
Results were analysed statistically by Student's t test (paired samples) or Wilcoxon's signed rank test where parametric methods of analysis were precluded by data not being normally distributed. (2) Grip strength (mmHg)
(3) Visual analogue pain score (Huskisson 1974) (4) Articular index (Ritchie et al. 1968) (5) Full blood count (6) ESR (Westergren) (7) Serum sulphydryl (SH) levels (Evans 1975) 
Results
(1) Fenclofenac v. placebo: Thirteen patients were admitted to the trial (one male, 12 female, age range 32 to 76 years). Eight patients, all female, completed the trial successfully. The details of the 5 who failed to complete the trial are shown in Table 2 . Of the 8 patients who completed the trial, all chose fenclofenac as the more effective agent for their rheumatic symptoms. When these preferences were plotted on the Armitage restricted design graph ( Fig 1) the boundary was crossed by the eighth patient and the trial stopped. The results of the other parameters measured and their significance are shown in Table 3 . In addition to a significant overall preference for fenclofenac, which determined when the trial should be stopped, four other parameters also showed a result in favour of fenclofenac at the 0.05 % level.
(2) Fenclofenac v. naproxen: Twenty-one patients were admitted to the trial (6 male and 15 female, age range 38 to 75 years). Fifteen patients, 5 male and 10 female, completed the trial successfully. Details of the 6 drop-outs are shown in Table 4 . Table 3 Results of mean (+ range) of parameters measured at end of fenclofenac and placebo periods (8 patients Of the 15 patients who completed the trial, 12 preferred fenclofenac and 2 preferred naproxen. One patient was unable to distinguish between the two, and this result is not included in the analysis of overall preferences. When plotted according to the Armitage restricted design, a significant result was reached after fourteen preferences (Fig 2) and the trial was closed. Analysis of the other parameters measured at each visit are shown inTable 5.
In addition to a significant overall preference for fenclofenac at the 0.05 % level, at which point the trial was stopped, four out of eight other parameters were significantly improved at the end of the fenclofenac period as compared with the naproxen period, and there was no significant difference in the other four parameters.
The total side-effects seen in both trials are detailed in Table 6 . Side-effects were more frequent with fenclofenac than with naproxen. There were no significant side-effects with the placebo.
The side-effects occurring on fenclofenac were sufficient to cause the patient to stop taking the drug in every case. The side-effects on naproxen were comparatively mild, and the patients were able to continue on the trial. One of the 4 patients developing a rash on fenclofenac did so on the thirteenth day of the trial, and was not withdrawn. Generally the rash appeared between the tenth and thirteenth day after taking the drug. It was generalized, itchy and erythematous. It disappeared within three days of stopping the drug, and there were no ill effects. The vertigo was temporary but severe, but this also disappeared rapidly after stopping the drug, again with no ill effects.
It is of interest that 3 of the 4 patients who developed rashes gave a history of an allergic rash to ampicillin; the fourth patient did not remember ever having had ampicillin. Other patients on the trials admitted to rashes on other drugs, such as gold and phenylbutazone, but appeared to be able to take fenclofenac without ill-effects.
Discussion
In short-term double-blind cross-over trials a clear-cut statistically significant preference for fenclofenac has been demonstrated, both when 900 mg daily was compared with a placebo, and when 1200 mg daily was compared with naproxen 500 mg daily. Naproxen was chosen for the latter comparison as propionic acid derivatives are widely held to be the drugs of first choice for patients with rheumatoid arthritis (Huskisson 1975) and as naproxen in this dosage was most frequently preferred when four propionic acid derivatives were compared (Huskisson et al. 1976 ). Naproxen also has the advantage of a similar twice daily dose schedule to fenclofenac.
Statistically significant improvement in morning stiffness, articular index, pain score and grip strength was shown with fenclofenac as compared with placebo in the first trial. A similar improvement was seen in the comparison with naproxen in the second trial, with the exception of the articular index, where no significant difference was ob-served. No change occurred in the hwemoglobin, ESR or sulphydryl (SH) levels in either trial.
Serum SH reactivity is known to be reduced in rheumatoid arthritis and other connective tissue disorders (Lorber et al. 1964) where the decrease is largely due to a fall in the level of slow-reacting SH groups. Increases in fast-reacting groups have been demonstrated following treatment with the acetic acid derivative alclofenac (Evans 1975) .
Summary and Conclusions
The short-term efficacy of fenclofenac has been demonstrated in two sequential, 2 x 2 week randomized, double-blind, cross-over trials where fenclofenac 900 mg daily was preferred to placebo, and 600 mg twice daily was preferred to 250 mg twice daily of naproxen. Significant improvement in pain scores, morning stiffness, articular index and grip strength was demonstrated. Side-effects included rashes and one case of vertigo, all of which cleared up rapidly on stopping the drug.
These studies suggest that fenclofenac may prove to be a useful drug in the therapy of rheumatoid arthritis and further long-term studies are advocated.
